CP-4126: Completed Phase II enrollment

Clavis completed enrollment of about 360 patients with metastatic pancreatic cancer in the open-label, international, pivotal Phase II LEAP trial comparing weekly 1,250 mg/m 2 IV CP-4126 for 3 out of ...